Peritoneal dialysis after nonrenal solid organ transplantation: Clinical outcomes and practical considerations

Peritoneal Dialysis International

Volumn 30, Issue 1, 2010, Pages 7-12

  Perl, Jeffrey ^a   Bargman, Joanne M ^a   Jassal, Sarbjit V ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Calcineurin inhibitor; Hemodialysis; Nonrenal solid organ transplantation; Survival

Indexed keywords

ANTIFUNGAL AGENT; CYCLOSPORIN; RAPAMYCIN;

BACTERIAL PERITONITIS; CAUSAL ATTRIBUTION; CLINICAL EFFECTIVENESS; HEART LUNG TRANSPLANTATION; HUMAN; IMMUNOTHERAPY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; NONHUMAN; ORGAN TRANSPLANTATION; PATHOGENESIS; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONITIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SAFETY; SCLEROSIS; SURVIVAL RATE; WOUND HEALING IMPAIRMENT;

HUMANS; KIDNEY FAILURE, CHRONIC; ORGAN TRANSPLANTATION; PERITONEAL DIALYSIS; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME;

EID: 77957227769     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2008.00215     Document Type: Review

References (52)

1. Ojo AO. Renal disease in recipients of nonrenal solid organ transplantation. Semin Nephrol 2007; 27:498-507.
2. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet 1999; 353:1083-1091.
3. Wilkinson AH, Cohen DJ. Renal failure in the recipients of nonrenal solid organ transplants. J Am Soc Nephrol 1999; 10:1136-1144.
4. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931-940.
5. van Gelder T, Balk AH, Zietse R, Hesse C, Mochtar B, Weimar W. Renal insufficiency after heart transplantation: a casecontrol study. Nephrol Dial Transplant 1998; 13:2322-2326.
6. Waser M, Maggiorini M, Binswanger U, Keusch G, Carrel T, von Segesser L, et al. Irreversibility of cyclosporine-induced renal function impairment in heart transplant recipients. J Heart Lung Transplant 1993; 12:846-850.
7. Greenberg A, Thompson ME, Griffith BJ, Hardesty RL, Kormos RL, el-Shahawy MA, et al. Cyclosporine nephrotoxicity in cardiac allograft patients-a seven-year followup. Transplantation 1990; 50:589-593.
8. Zaltzman JS, Pei Y, Maurer J, Patterson A, Cattran DC. Cyclosporine nephrotoxicity in lung transplant recipients. Transplantation 1992; 54:875-878.
9. Pattison JM, Petersen J, Kuo P, Valantine V, Robbins RC, Theodore J. The incidence of renal failure in one hundred consecutive heart-lung transplant recipients. Am J Kidney Dis 1995; 26:643-648.
10. Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 1994; 58:170-178.
11. Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 1998; 66:59-66.
12. Sehgal V, Radhakrishnan J, Appel GB, Valeri A, Cohen DJ. Progressive renal insufficiency following cardiac transplantation: cyclosporine, lipids, and hypertension. Am J Kidney Dis 1995; 26:193-201.
13. Alam A, Badovinac K, Ivis F, Trpeski L, Cantarovich M. The outcome of heart transplant recipients following the development of end-stage renal disease: analysis of the Canadian Organ Replacement Register (CORR). Am J Transplant 2007; 7:461-465.
14. Al Riyami D, Alam A, Badovinac K, Ivis F, Trpeski L, Cantarovich M. Decreased survival in liver transplant patients requiring chronic dialysis: a Canadian experience. Transplantation 2008; 85:1277-1280.
15. Gill JS, Abichandani R, Khan S, Kausz AT, Pereira BJ. Opportunities to improve the care of patients with kidney transplant failure. Kidney Int 2002; 61:2193-2200.
16. Greenberg A, Egel JW, Thompson ME, Hardesty RL, Griffith BP, Bahnson HT, et al. Early and late forms of cyclosporine nephrotoxicity: studies in cardiac transplant recipients. Am J Kidney Dis 1987; 9:12-22.
17. Coopersmith CM, Brennan DC, Miller B, Wang C, Hmiel P, Shenoy S, et al. Renal transplantation following previous heart, liver, and lung transplantation: an 8-year singlecenter experience. Surgery 2001; 130:457-462.
18. Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTx) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001; 72:1934-1939.
19. Bloom RD, Reese PP. Chronic kidney disease after nonrenal solid-organ transplantation. J Am Soc Nephrol 2007; 18: 3031-3041.
20. Lewis RM, Verani RR, Vo C, Katz SM, Van Buren CT, Radovancevic B, et al. Evaluation of chronic renal disease in heart transplant recipients: importance of pretransplantation native kidney histologic evaluation. J Heart Lung Transplant 1994; 13:376-380.
21. Boyle JM, Moualla S, Arrigain S, Worley S, Bakri MH, Starling RC, et al. Risks and outcomes of acute kidney injury requiring dialysis after cardiac transplantation. Am J Kidney Dis 2006; 48:787-796.
22. Kunst H, Thompson D, Hodson M. Hypertension as a marker for later development of end-stage renal failure after lung and heart-lung transplantation: a cohort study. J Heart Lung Transplant 2004; 23:1182-1188.
23. Veillon S, Caillard S, Epailly E, Eisenmann B, Hannedouche T, Moulin B. Chronic renal failure after cardiac transplantation: predictive factors and influence on mortality-results of a monocenter study in 141 patients. Transplant Proc 2002; 34:2819-2820.
24. Crawford DH, Endre ZH, Axelsen RA, Lynch SV, Balderson GA, Strong RW, et al. Universal occurrence of glomerular abnormalities in patients receiving liver transplants. Am J Kidney Dis 1992; 19:339-344.
25. Axelsen RA, Crawford DH, Endre ZH, Lynch SV, Balderson GA, Strong RW, et al. Renal glomerular lesions in unselected patients with cirrhosis undergoing orthotopic liver transplantation. Pathology 1995; 27:237-246.
26. Hmiel SP, Beck AM, de la Morena MT, Sweet S. Progressive chronic kidney disease after pediatric lung transplantation. Am J Transplant 2005; 5:1739-1747.
27. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 2008; 22:1-15.
28. Villar E, Boissonnat P, Sebbag L, Hendawy A, Cahen R, Trolliet P, et al. Poor prognosis of heart transplant patients with end-stage renal failure. Nephrol Dial Transplant 2007; 22:1383-1389.
29. Bernardini J, Piraino B, Kormos RL. Patient survival with renal replacement therapy in heart transplantation patients. ASAIO J 1998; 44: M546-M548.
30. Ahmad M, Richardson R, Bargman JM, Oreopoulos D. Advantages of peritoneal dialysis in comparison to hemodialysis, in cardiac allograft recipients with end stage renal disease. Int Urol Nephrol 2008; 40:1083-1087.
31. Jayasena SD, Riaz A, Lewis CM, Neild GH, Thompson FD, Woolfson RG. Outcome in patients with end-stage renal disease following heart or heart-lung transplantation receiving peritoneal dialysis. Nephrol Dial Transplant 2001; 16:1681-1685.
32. Wong PN, Lo KY, Tong GM, Chan SF, Lo MW, Mak SK, et al. Prevention of fungal peritonitis with nystatin prophylaxis in patients receiving CAPD. Perit Dial Int 2007; 27:531-536.
33. Perl J, Jassal SV, Bargman JM. Persistent peritoneal dialysis catheter exit-site leak in a patient receiving maintenance immunosuppression with sirolimus. Clin Transplant 2008; 22:672-673.
34. Dean PG, Lund WJ, Larson TS, Prieto M, Nyberg SL, Ishitani MB, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004; 77: 1555-1561.
35. Badve SV, Hawley CM, McDonald SP, Mudge DW, Rosman JB, Brown FG, et al. Effect of previously failed kidney transplantation on peritoneal dialysis outcomes in the Australian and New Zealand patient populations. Nephrol Dial Transplant 2006; 21:776-783.
36. van Westrhenen R, Aten J, Hajji N, de Boer OJ, Kunne C, de Waart DR, et al. Cyclosporin A induces peritoneal fibrosis and angiogenesis during chronic peritoneal exposure to a glucose-based, lactate-buffered dialysis solution in the rat. Blood Purif 2007; 25:466-472.
37. Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000; 20(Suppl 4):S43-S55.
38. Fieren MW, Betjes MG, Korte MR, Boer WH. Posttransplant encapsulating peritoneal sclerosis: a worrying new trend? Perit Dial Int 2007; 27:619-624.
39. Korte MR, Yo M, Betjes MG, Fieren MW, van Saase JC, Boer WH, et al. Increasing incidence of severe encapsulating peritoneal sclerosis after kidney transplantation. Nephrol Dial Transplant 2007; 22:2412-2414.
40. de Freitas D, Augustine T, Hurst H, Taylor P, Williams R, Hutchison A, et al. Encapsulating peritoneal sclerosis following renal transplantation despite tamoxifen and immunosuppressive therapy. Nephrol Dial Transplant Plus 2008; 1:333-335.
41. Maguire D, Srinivasan P, O'Grady J, Rela M, Heaton ND. Sclerosing encapsulating peritonitis after orthotopic liver transplantation. Am J Surg 2001; 182:151-154.
42. Kes P, Slavicek J. [Prevention and treatment of hepatitis C in patients on dialysis]. Acta Med Croatica 2005; 59: 483-490.
43. Cusumano AM, Poratto F, del Pino N, Fernandez JL, Vilches A. Identification of hepatitis C virus RNA in peritoneal dialysis fluid of patients with viremia. Perit Dial Int 2005; 25:478-482.
44. Blake PG. Integrated end-stage renal disease care: the role of peritoneal dialysis. Nephrol Dial Transplant 2001; 16(Suppl 5):61-66.
45. Selgas R, Bajo MA, Jimenez C, Sanchez C, Del Peso G, Cacho G, et al. Peritoneal dialysis in liver disorders. Perit Dial Int 1996; 16(Suppl 1):S215-S219.
46. Jansen MA, Hart AA, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 2002; 62:1046-1053.
47. Lysaght MJ, Vonesh EF, Gotch F, Ibels L, Keen M, Lindholm B, et al. The influence of dialysis treatment modality on the decline of remaining renal function. ASAIO Trans 1991; 37:598-604.
48. Raja RM, Krasnoff SO, Moros JG, Kramer MS, Rosenbaum JL. Repeated peritoneal dialysis in treatment of heart failure. JAMA 1970; 213:2268-2269.
49. McKinnie JJ, Bourgeois RJ, Husserl FE. Long-term therapy for heart failure with continuous ambulatory peritoneal dialysis. Arch Intern Med 1985; 145:1128-1129.
50. Moist LM, Port FK, Orzol SM, Young EW, Ostbye T, Wolfe RA, et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000; 11: 556-564.
51. Rottembourg J, Issad B, Allouache M, Jacobs C. Recovery of renal function in patients treated by CAPD. Adv Perit Dial 1989; 5:63-66.
52. Katz IJ, Sofianou L, Butler O, Hopley M. Recovery of renal function in black South African patients with malignant hypertension: superiority of continuous ambulatory peritoneal dialysis over hemodialysis. Perit Dial Int 2001; 21: 581-586.